

A24 frequency was expressed as the number of transformants per μg DNA per viable recipient at the time of DNA added.

In the Claims:

✓
Please cancel claims 7-21 and 34-37.

✓
Please replace claims 3-6 and 24, 29, 30 and 32 with the following amended claims.

Sub D
3. (Amended) The compound of claim 2, comprising a derivative of [SEQ ID NO:2] or [SEQ ID NO:4], a fragment of [SEQ ID NO:2] or [SEQ ID NO:4] or a derivative of a fragment of [SEQ ID NO:2] or [SEQ ID NO:4].

A25 4. (Amended) The compound of claim 3, wherein amino acids are removed from the N-terminus and/or C-terminus of [SEQ ID NO:2] or [SEQ ID NO:4].

5. (Amended) A pharmaceutical composition comprising all or part of the peptide of claim 1 and a carrier.

6. (Amended) A method of medical treatment or prophylaxis of caries or endocarditis, comprising administering the compound of claim 1.

A26 Sub D
24. (Amended) The polypeptide of claim 23 comprising all or part of an amino acid sequence in [SEQ ID NO:2] or [SEQ ID NO:4].

A27 Sub D
29. (Amended) An isolated nucleic acid molecule encoding the polypeptide of any of claims 22 to 28.

30. (Amended) An antibody directed against the polypeptide of any of claims 22 to 28.

A28 Sub D
32. (Amended) A vaccine composition comprising all or part of the peptide of any of claims 22 to 28 and a carrier.

REMARKS

Applicants acknowledge receipt of the "Notice to File Missing Parts of Nonprovisional Application" dated May 17, 2001. In reply, an executed Declaration is submitted herewith. The associated "Application Data Sheet" was filed with the Application on April 10, 2001. Payment of the required fees, surcharge, and extension fee is provided. A Sequence Listing in computer readable form and in written form are attached hereto, along with a statement in compliance with 37 CFR 1.821et seq.